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PURPOSE

RESULT(S)

• Retinoblastoma (RB) is a rare form of cancer that rapidly develops from the immature cells of the retina and the
light-detecting tissue of the eye.
• The treatment options of RB has been limited to enucleation, external beam radiotherapy, episcleral plaque
radiotherapy and cryotherapy. However, these are frequently associated with complications, such as facial
deformities, cataract, radiation retinopathy and a substantial risk of secondary tumors.
• Paclitaxel (Ptx) is a potent chemo agent and is widely used in the treatment of RB. However, its clinical use is
limited by systemic toxicity, rapid clearance and resistance. Moreover, the blood-retinal barrier (BRB) also limits
the potential use of Ptx.
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Figure 2 – Effect of lipid concentration on the particle size of Ptx-NLC
formulations on storage at 4°C
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Figure 3 – Effect of lipid concentration on the PDI of Ptx-NLC formulations on
storage at 4°C

OBJECTIVE(S)
The aim of this study was to prepare and characterize nanostructured lipid carriers (NLC) of Ptx (Ptx-NLC) and
effect of PEGylation of Ptx-NLC (Ptx-PEG-NLC) on ocular delivery with respect to problems related to drug
delivery, retention and penetration through the BRB.

METHOD(S)

Lipid ratio optimization : The effect of the lipid ratio on the
particle size, PDI and stability of the NLC was evaluated through
the different levels of α-Tocopherol succinate (αTS) and the ratio
of αTs to Capryol 90 (CP90) (Table 1). Polysorbate®80 and
Poloxamer® 188 were used as stabilizers.
Characterization of Ptx-NLC and Ptx-PEG-NLC:
Physical characteristics: Particle size, PDI and Zeta Potential
were determined using a zetasizer Nano ZS Zen 3600 (Malvern
Instrument).

a-TS (mg)
300
300
300
400
400
400
500
500
500

CP90 (mg)
100
150
200
133
200
267
167
250
333

Ptx (mg)
10
10
10
10
10
10
10
10
10

Ratio
(Cp90/aTS)
1/3
1/2
2/3
1/3
1/2
2/3
1/3
1/2
2/3

Table 1 – Formulations for optimizing lipid ratio
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Figure 5- Photographs of Formulations Figure 6- Drug release from the optimized Ptx-NLC

CONCLUSION(S)

Assay – Ptx content in Ptx-NLC and Ptx-PEG-NLC formulation
was analyzed using HPLC method.
Release study -The release study was performed using dialysis
cassette, using 5%w/v hydroxyl propyl beta cyclodextrin (HPβCD)
solution in isotonic phosphate buffer saline (IPBS, pH 7.4) and the
drug was quantified using HPLC.
Statistical Analysis – Repeated Measures ANOVA was performed
to evaluate the effect of the process variables of Ptx-NLC.

Figure 4 - Effect of PEGylation on the particle size, PDI and zeta potential of the Ptx-NLC formulations stored at 4°C

% Drug Release

Preparation of Ptx-NLC and Ptx-PEG-NLC: Ptx-NLC and PtxPEG-NLC formulations were prepared by homogenization and
ultrasonication method (Figure 1).

Lipid ratio optimization

Figure 1- Schematic for preparation of NLC formulations

• The paclitaxel loaded NLC formulations were successfully
prepared with α-Tocopherol succinate as a solid lipid and
characterized.
• The PEGylation had a significant effect on the particle size,
PDI and zeta potential of Ptx-NLC formulation.
• The optimized Ptx-NLC and Ptx-PEG-NLC formulations
showed no significant difference (p>0.05) in assay and
entrapment efficiency of over 60 days (last-time point
checked) at 4°C .
• The Ptx-NLC showed the sustained release of drug when
compared to the pure drug solution as control .

Figure 7 - DSC thermograms of DSP-PEG-2k, PTX and αTS
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